Spartina Biotechnologies, Inc.

 Spartina Biotechnologies, Inc. contact information is shown below
Owner:SPARTINA BIOTECHNOLOGIES, INC.
Owner Address:3900 Paseo del Sol Santa Fe NM 87507
Owner Web Site
Owner Phone
Owner Toll Free
Owner Fax

 

Brands Owned bySpartina Biotechnologies, Inc.

Brand:

ADDS

Description:

Research and development in the fields of pharmaceuticals, therapeutics, and biologics, namely, exosome-based delivery systems for pharmaceuticals, therapeutics, and biologics; Medical research and development in the field of molecular biology, genetic engineering, drug delivery, and bioinformatics; Research and development of delivery systems for therapeutic compounds, namely, exosome-based drug delivery systems for therapeutic compounds for the treatment of viral pathogens, cancer and inherited disorder in humans; Research and development of delivery systems for therapeutic compounds, namely, exosome-based drug delivery of therapeutic compounds; Research and development of delivery systems for therapeutic nucleic acids, namely, exosome-based drug delivery of therapeutic nucleic acids, namely, RNA; Research and development of delivery systems for therapeutic peptides, namely, exosome-based drug delivery of therapeutic peptides; Research and development of delivery systems for gene-editing proteins, namely, exosome-based drug delivery of gene-editing proteins; Research and development of delivery systems for vaccines, namely, exosome-based drug delivery systems for vaccines; Research and development of delivery systems for vaccines, namely, exosome-based drug delivery systems for pharmaceutical compounds; Research and development of the production of exosomes for therapeutic uses, namely, yeast-based exosome for therapeutic uses; Research and development of new biological products for therapeutic use; Design and development of nucleic acids, proteins, enzymes, and drug compounds for use in pharmaceuticals, biotechnology, medical, and diagnostic applications;

Category: RESEARCH DEVELOPMENT
Brand:

CELERNA

Description:

Research and development in the fields of pharmaceuticals, therapeutics, and biologics, namely, exosome-based delivery systems for pharmaceuticals, therapeutics, and biologics; Medical research and development in the field of molecular biology, genetic engineering, drug delivery, and bioinformatics; Research and development of delivery systems for therapeutic compounds, namely, exosome-based drug delivery systems for therapeutic compounds for the treatment of viral pathogens, cancer and inherited disorder in humans; Research and development of delivery systems for therapeutic compounds, namely, exosome-based drug delivery of therapeutic compounds; Research and development of delivery systems for therapeutic nucleic acids, namely, exosome-based drug delivery of therapeutic nucleic acids, namely, RNA; Research and development of delivery systems for therapeutic peptides, namely, exosome-based drug delivery of therapeutic peptides; Research and development of delivery systems for gene-editing proteins, namely, exosome-based drug delivery of gene-editing proteins; Research and development of delivery systems for vaccines, namely, exosome-based drug delivery systems for vaccines; Research and development of the production of exosomes for therapeutic uses, namely, yeast-based exosome for therapeutic uses; Research and development of new biological products for therapeutic use; Design and development of nucleic acids, proteins, enzymes, and drug compounds for use in pharmaceuticals, biotechnology, medical, and diagnostic applications;

Category: RESEARCH DEVELOPMENT